Katherine Stueland Sells 1,078 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 1,078 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $89.44, for a total transaction of $96,416.32. Following the transaction, the chief executive officer now owns 6,674 shares in the company, valued at approximately $596,922.56. The trade was a 13.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Monday, March 17th, Katherine Stueland sold 10,559 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total value of $1,021,160.89.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The stock was sold at an average price of $94.73, for a total value of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The shares were sold at an average price of $78.18, for a total value of $1,407,709.08.

GeneDx Stock Down 4.1 %

GeneDx stock traded down $4.01 during midday trading on Monday, reaching $94.46. The stock had a trading volume of 668,407 shares, compared to its average volume of 612,654. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 12 month low of $7.72 and a 12 month high of $115.60. The company has a fifty day moving average price of $84.69 and a two-hundred day moving average price of $70.37. The company has a market capitalization of $2.65 billion, a P/E ratio of -48.19 and a beta of 1.91.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The business had revenue of $95.64 million during the quarter, compared to the consensus estimate of $82.24 million. As a group, equities analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Institutional Trading of GeneDx

A number of institutional investors and hedge funds have recently modified their holdings of WGS. William Blair Investment Management LLC bought a new position in shares of GeneDx during the 4th quarter valued at approximately $51,496,000. Lord Abbett & CO. LLC purchased a new stake in GeneDx during the 4th quarter worth about $48,458,000. Summit Partners Public Asset Management LLC grew its holdings in GeneDx by 336.9% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 755,564 shares of the company’s stock valued at $58,073,000 after buying an additional 582,619 shares in the last quarter. Science & Technology Partners L.P. purchased a new position in GeneDx during the 4th quarter valued at about $30,821,000. Finally, Fred Alger Management LLC purchased a new stake in shares of GeneDx in the third quarter worth about $16,731,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. The Goldman Sachs Group boosted their price objective on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen increased their target price on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $72.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.